NCT00759551 - Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension | Biotech Hunter

Enrollment

555

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions

Hypertension

Interventions

DRUG

Azilsartan

Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan

Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan

Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan

Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

DRUG

Azilsartan

Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.

DRUG

Placebo

Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.

DRUG

Olmesartan

Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.